Abstract 2345: Development of a novel diagnostic system for bile duct cancer using urinary metabolites

Background and Aim: Urine contains numerous small molecular metabolites that can be used as reliable, non-invasive cancer biomarkers. The aim of this study was to identify biomarkers for bile duct cancer by comprehensively analyzing urinary metabolites from patients with bile duct cancer. Materials and Methods: This study was carried out on urine samples collected before and after tumor resection in 13 patients with bile duct cancer. Urine metabolites were extracted using liquid chromatography/mass spectrometry. Biomarker candidates were identified using the Wilcoxon rank-sum test, random forest method, and orthogonal partial least squares discriminant analysis. Results: We developed an AI technology that efficiently searched for urine tumor markers based on the detailed medical information of each urine sample and used them to construct cancer test models. About 1500 metabolites, such as amino acids, nucleic acids, and lipids, were detected in one urine sample. Ten urine tumor marker candidates for bile duct cancer were identified. Conclusions: We identified novel urine tumor marker candidates for bile duct cancer. We are currently investigating additional urine samples from 23 patients with bile duct cancer. The possibility of detecting and monitoring bile duct cancer using urine tumor markers has been examined. Citation Format: Hizuru Amano, Akinari Hinoki, Hiroo Uchida, Kazuki Yokota, Takashi Ishigaki, Minoru Sakairi, Mayumi Abe, Yasushi Terui, Hirohisa Oda, Takahisa Tainaka, Chiyoe Shirota, Wataru Sumida, satoshi Makita, Aitaro Takimoto, Masamune Okamoto, Akihiro Yasui, Yoichi Nakagawa. Development of a novel diagnostic system for bile duct cancer using urinary metabolites [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2345.